AIDS Alert Archives – December 1, 2005
December 1, 2005
View Issues
-
Latest STD data in United States continues to portend problems with prevention, HIV
The national picture on sexually-transmitted diseases (STDs) shows a positive trend of a decline in new infections of gonorrhea, while the rates of syphilis infections is increasing among men who have sex with men (MSM), and chlamydia remains a major health threat, especially to young women. -
New research finds possible treatment for latent HIV
Researchers have discovered a possible combination therapy that will help clear HIV from resting CD4 T-cells, which may open the doors to a new approach to eliminating HIV infection. -
Protein in St. John’s Wort may suppresses HIV-1 gene expression
St. Johns Wort contains a protein that inhibits HIV-1 replication, according to new research. -
Adherence Strategies: HIV pill reminder device shows some adherence improvement
Researchers studying a population of HIV patients found that a pill reminder improved adherence for those who were memory impaired. -
Drug resistance found in SE area, representing poor, rural population
A recent study about HIV drug resistance among untreated HIV patients highlights the growing problem of resistance in a Southeastern region of the country. -
Updated guidelines issued for occupational PEP use
The U.S. Public Health Service has changed its treatment guidelines for the use of postexposure prophylaxis (PEP), following an occupational exposure to HIV infection. -
FDA Notifications
The FDA announced on Nov. 4, 2005, the tentative approval of Lamivudine Oral Solution, 10 mg/mL manufactured by Aurobindo Pharma LTD. of Hyderabad, India. Lamivudine Oral Solution is the first generic version of the already approved Epivir Oral Solution, 10 mg/mL, manufactured by GlaxoSmithKline. This child-friendly-product is indicated for use in pediatric patients with HIV from three months to 16 years.